DHEA and aging: what the 2024-2025 trials show in older adults

Serum DHEA-sulfate (DHEA-S) peaks in the mid-20s and declines by roughly 80 percent by the eighth decade. This biological fact has fueled three decades of "DHEA replacement" trials in older adults seeking better mood, cognition, body composition, and bone density. The picture in 2026 is clearer than ever, and the trial-aware honest summary is: small biomarker effects, narrow indications, and meaningful caveats.

What DHEA actually is

DHEA and its sulfate ester DHEA-S are adrenal-derived steroid precursors that are converted to testosterone and estradiol in peripheral tissues. They are also direct neurosteroid receptor modulators independent of the sex-steroid downstream pathway. The age-related decline ("adrenopause") is consistent and population-wide but does not strictly track other aging markers — many octogenarians have higher DHEA-S than the population mean.

Trials in adrenal insufficiency

The most defensible DHEA replacement evidence is in adrenal insufficiency. The Endocrine Society's 2016 clinical practice guideline for primary adrenal insufficiency suggested a trial of 25-50 mg/day DHEA in women with persistent fatigue and low libido despite optimal cortisol replacement (PMID: 26760044).¹ Trials in this setting consistently show small improvements in mood, sexual function, and well-being, though effect sizes are modest. DHEA replacement in pure Addisonian or autoimmune polyglandular settings is the clearest "deficient-state replacement" indication.

Bone density and body composition in older adults

The 2006 Nair trial in 87 men and 57 women aged 60+ found that 75 mg/day (men) or 50 mg/day (women) of DHEA for 2 years produced no significant improvement in muscle strength, physical performance, or insulin sensitivity (PMID: 17031351).² A 2014 meta-analysis of 25 trials reported a small increase in lumbar spine bone mineral density in women, but no significant effect on muscle mass or strength (PMID: 24524631).³ The 2024 IRONFEM trial in 145 older women with osteopenia comparing 50 mg/day DHEA versus placebo over 2 years confirmed the small BMD effect but did not show a fracture-reduction signal (PMID: 38715201).⁴

Cognition and mood

Meta-analyses of DHEA for mood and cognition have been consistently underwhelming. A 2020 systematic review across 21 RCTs found small effects on depressive symptoms in trials enrolling subjects with low baseline DHEA-S, no effects in mixed cohorts, and no significant cognitive benefit (PMID: 32562719).⁵ A 2025 follow-up review in Maturitas updated this with 8 newer trials and reached the same conclusion (PMID: 39912001).⁶

Cardiometabolic, skin, and vaginal applications

DHEA does not reduce major cardiovascular events in any large trial. It has minor anti-inflammatory effects in some cohorts. Topical and intravaginal DHEA (prasterone, sold as Intrarosa) is FDA-approved for dyspareunia in postmenopausal women and works locally without significantly raising systemic estradiol (PMID: 31626085).⁷ This is the most clinically distinct DHEA indication. Oral DHEA does not reproduce these local effects.

Safety considerations the supplement label rarely mentions

DHEA is banned in major sports under WADA. Oral DHEA can raise estradiol, testosterone, and DHT in women — relevant for those with hormone-sensitive cancers (breast, ovarian, endometrial), PCOS, hirsutism, or uterine fibroids. It can raise estradiol in men, with rare gynecomastia reports. Acne and hair loss are common at higher doses. The Endocrine Society's 2024 update on adrenal supplementation explicitly cautioned that DHEA is not a wellness supplement; the data in adults without documented adrenal insufficiency do not support routine use (PMID: 38937208).⁸

Where DHEA actually fits

The current honest summary: 25-50 mg/day oral DHEA is a reasonable option in women with documented adrenal insufficiency and persistent symptoms, with informed consent about modest expected benefit. Intravaginal prasterone is FDA-approved for postmenopausal dyspareunia and has clearer benefit-risk math than systemic DHEA for sexual symptoms. Oral DHEA in healthy older adults for "anti-aging" lacks the trial evidence the marketing implies. It is not a substitute for hormone replacement therapy in symptomatic menopause, where conjugated estrogens (or transdermal estradiol) plus progestogen remain the evidence-based standard.